Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis.
The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00298714
|Principal Investigator:||Pere Ginès, M.D.||Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona|
|Study Chair:||Vicente Arroyo, M.D.||Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona|